Immunotherapy duo after radiation shows promise for untreatable liver cancer
NCT ID NCT04605731
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) after a targeted radiation treatment can help control advanced liver cancer that cannot be removed by surgery. The study involves 25 adults with liver cancer that has spread locally. The main goals are to check for side effects and see if the combination shrinks tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BCLC STAGE B HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy combo tested against untreatable liver cancer
- New drug zanzalintinib tested for advanced liver cancer
- Liver cancer drug combo shows promise in large trial
- New hope for liver cancer patients with cirrhosis? tiny trial tests drug duo
- Home monitoring may keep cancer patients out of the ER
- New radioactive beads aim to outperform standard liver cancer therapy